Som for andre DNA- beskadigende antineoplastiske stoffer har sekundære akutte myeloide leukæmier og myelodysplasier været rapporteret hos patienter, der har fået kombinationsbehandling med doxorubicin.
As with other DNA-damaging antineoplastic agents, secondary acute myeloid leukemias and myelodysplasias have been reported in patients having received combined treatment with doxorubicin.